Steven Valiquette
Stock Analyst at Mizuho
(3.32)
# 986
Out of 5,182 analysts
128
Total ratings
50.75%
Success rate
3.45%
Average return
Main Sectors:
Stocks Rated by Steven Valiquette
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PHR Phreesia | Maintains: Outperform | $22 → $19 | $9.62 | +97.51% | 3 | Mar 24, 2026 | |
| LFMD LifeMD | Upgrades: Outperform | $6 → $8 | $4.57 | +75.05% | 3 | Mar 16, 2026 | |
| XRAY DENTSPLY SIRONA | Maintains: Neutral | $14 → $16 | $11.96 | +33.78% | 9 | Mar 2, 2026 | |
| GDRX GoodRx Holdings | Maintains: Neutral | $4 → $3 | $2.28 | +31.58% | 2 | Feb 27, 2026 | |
| HSIC Henry Schein | Maintains: Neutral | $81 → $88 | $77.20 | +13.99% | 7 | Feb 25, 2026 | |
| DOCS Doximity | Maintains: Neutral | $45 → $34 | $24.66 | +37.88% | 4 | Feb 10, 2026 | |
| NVST Envista Holdings | Maintains: Neutral | $24 → $27 | $26.77 | +0.86% | 4 | Feb 10, 2026 | |
| CAH Cardinal Health | Maintains: Outperform | $222 → $235 | $202.34 | +16.14% | 8 | Feb 6, 2026 | |
| MCK McKesson | Maintains: Neutral | $880 → $885 | $828.32 | +6.84% | 5 | Feb 5, 2026 | |
| ALGN Align Technology | Maintains: Outperform | $170 → $200 | $184.70 | +8.28% | 13 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $85 → $100 | $69.78 | +43.31% | 3 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $45.23 | +6.12% | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $340 → $380 | $310.16 | +22.52% | 3 | Nov 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $48 → $50 | $25.70 | +94.55% | 2 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $295 → $325 | $160.45 | +102.56% | 4 | Aug 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $10 | $5.85 | +70.94% | 1 | Jul 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $126 | $83.47 | +50.95% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $5 | $5.18 | -3.47% | 1 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $142 | $179.51 | -20.90% | 10 | Sep 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $55 | $84.70 | -35.06% | 6 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $82 → $92 | $210.00 | -56.19% | 10 | Aug 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $565 | $354.69 | +59.29% | 5 | Apr 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $100 | $78.36 | +27.62% | 1 | Mar 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $380 → $400 | $179.22 | +123.19% | 4 | Oct 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Overweight | $107 | $43.50 | +145.98% | 1 | Jul 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $22 → $17 | $38.76 | -56.14% | 3 | Apr 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $5 → $12 | $13.95 | -13.98% | 1 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $96 | $100.92 | -4.88% | 3 | Nov 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $105 → $120 | $196.63 | -38.97% | 6 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $117 → $127 | $445.77 | -71.51% | 1 | Apr 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $327 → $358 | $223.62 | +60.09% | 3 | Dec 6, 2019 |
Phreesia
Mar 24, 2026
Maintains: Outperform
Price Target: $22 → $19
Current: $9.62
Upside: +97.51%
LifeMD
Mar 16, 2026
Upgrades: Outperform
Price Target: $6 → $8
Current: $4.57
Upside: +75.05%
DENTSPLY SIRONA
Mar 2, 2026
Maintains: Neutral
Price Target: $14 → $16
Current: $11.96
Upside: +33.78%
GoodRx Holdings
Feb 27, 2026
Maintains: Neutral
Price Target: $4 → $3
Current: $2.28
Upside: +31.58%
Henry Schein
Feb 25, 2026
Maintains: Neutral
Price Target: $81 → $88
Current: $77.20
Upside: +13.99%
Doximity
Feb 10, 2026
Maintains: Neutral
Price Target: $45 → $34
Current: $24.66
Upside: +37.88%
Envista Holdings
Feb 10, 2026
Maintains: Neutral
Price Target: $24 → $27
Current: $26.77
Upside: +0.86%
Cardinal Health
Feb 6, 2026
Maintains: Outperform
Price Target: $222 → $235
Current: $202.34
Upside: +16.14%
McKesson
Feb 5, 2026
Maintains: Neutral
Price Target: $880 → $885
Current: $828.32
Upside: +6.84%
Align Technology
Jan 20, 2026
Maintains: Outperform
Price Target: $170 → $200
Current: $184.70
Upside: +8.28%
Jan 20, 2026
Upgrades: Outperform
Price Target: $85 → $100
Current: $69.78
Upside: +43.31%
Jan 12, 2026
Initiates: Outperform
Price Target: $48
Current: $45.23
Upside: +6.12%
Nov 6, 2025
Maintains: Outperform
Price Target: $340 → $380
Current: $310.16
Upside: +22.52%
Oct 30, 2025
Maintains: Outperform
Price Target: $48 → $50
Current: $25.70
Upside: +94.55%
Aug 29, 2025
Maintains: Outperform
Price Target: $295 → $325
Current: $160.45
Upside: +102.56%
Jul 25, 2025
Initiates: Neutral
Price Target: $10
Current: $5.85
Upside: +70.94%
Dec 4, 2024
Initiates: Outperform
Price Target: $126
Current: $83.47
Upside: +50.95%
Dec 4, 2024
Initiates: Outperform
Price Target: $5
Current: $5.18
Upside: -3.47%
Sep 21, 2023
Maintains: Equal-Weight
Price Target: $142
Current: $179.51
Upside: -20.90%
Aug 4, 2023
Maintains: Overweight
Price Target: $55
Current: $84.70
Upside: -35.06%
Aug 2, 2023
Maintains: Overweight
Price Target: $82 → $92
Current: $210.00
Upside: -56.19%
Apr 14, 2023
Maintains: Overweight
Price Target: $565
Current: $354.69
Upside: +59.29%
Mar 30, 2023
Maintains: Overweight
Price Target: $110 → $100
Current: $78.36
Upside: +27.62%
Oct 28, 2022
Maintains: Overweight
Price Target: $380 → $400
Current: $179.22
Upside: +123.19%
Jul 28, 2022
Reinstates: Overweight
Price Target: $107
Current: $43.50
Upside: +145.98%
Apr 18, 2022
Downgrades: Equal-Weight
Price Target: $22 → $17
Current: $38.76
Upside: -56.14%
Jun 11, 2021
Upgrades: Overweight
Price Target: $5 → $12
Current: $13.95
Upside: -13.98%
Nov 23, 2020
Upgrades: Overweight
Price Target: $96
Current: $100.92
Upside: -4.88%
Apr 30, 2020
Reiterates: Neutral
Price Target: $105 → $120
Current: $196.63
Upside: -38.97%
Apr 22, 2020
Maintains: Overweight
Price Target: $117 → $127
Current: $445.77
Upside: -71.51%
Dec 6, 2019
Maintains: Overweight
Price Target: $327 → $358
Current: $223.62
Upside: +60.09%